healthcare investor
What will be the most significant biotech development over the next decade? What cutting-edge treatment will change our perspective on common diseases? Curiosity is an important part of our business DNA – together with our strong belief in long-term value creation.
The name p53 originates from one of the most investigated molecules ever – the p53 protein, also known as the guardian of the genome.
P53 was founded in November 2018. We are part of the family-owned Stavanger based investment company TD Veen. All investments are made in line with TD Veen’s overall strategy and objective, where sustainable development and a scalable business model are particularly emphasized. However, P53 is solely dedicated to investing in the healthcare sector.
The p53 team: Silje Veen, Øyvind Schanke, Kjell Skappel and Susanne Stuffers
In our core investments, P53 shall be an active owner, preferably with one or more co-investors who are considered to share our approach and mindset. In addition to long-term capital, we aim to contribute with our knowledge, experience, and network. Our active positions are exercised through (active) board participation and in close collaboration with the company’s management and other shareholders.
Susanne holds an M.D. degree from the Erasmus University Rotterdam, Netherlands, and a Ph.D. degree in cancer biomedicine from the Norwegian Radiumhospital.
Susanne holds an M.D. degree from the Erasmus University Rotterdam, Netherlands, and a Ph.D. degree in cancer biomedicine from the Norwegian Radiumhospital.
She gained broad experience in healthcare and life sciences, covering the sector from several angles. Susanne was a management consultant in health care (public and private) and life sciences at EY, served in medical and commercial roles in the pharmaceutical industry (Novartis), and has clinical practice as a resident in oncology. She worked with Arctic Securities as an equity analyst covering the healthcare sector, before joining forces with T.D. Veen to co-found and lead p53.
Susanne has supported life science companies in different phases of development, from start-up to late clinical stage, and has experience from financial markets including private placements and IPOs.
Lars holds a master’s degree in molecular biology from Oslo University, where the research was conducted at the Norwegian Radiumhospital.
After completing his master’s, he worked at the Institute for cancer research at the Norwegian Radiumhospital for several years and contributed to research projects which resulted in published articles. He is currently in the process of compiling this research into a PhD. Following his interest in the capital markets, he subsequently joined Arctic Securities as an equity research analyst covering healthcare, before joining p53 Invest.
Øyvind is Chief Investment Officer in TD Veen. He holds an MBA from NHH (Norwegian School of Economics) He has over 25 years of investment experience. Øyvind was previously the CEO of Skagen Funds.
Øyvind holds an MBA from NHH (Norwegian School of Economics) He has over 25 years of investment experience. Øyvind was previously the CEO of Skagen Funds. Prior to that he spent almost 16 years at the Norwegian Sovereign Wealth fund, the last years as the CIO for asset management based in London.
Silje has a degree in marketing from The Norwegian Buisness School, BI specializing in local business development.
Silje has a degree in marketing from The Norwegian Buisness School, BI specializing in local business development. She founded the food concept Food Story and managed it for more than 10 years. She is also chair of the board in TD Veen.
Kjell is the founding partner of Stavanger Venture AS, a privately held Value Adding angel to venture phase Investment Company.
Kjell is CEO in TD Veen, and the founding partner of Stavanger Venture AS, a privately held value adding angel to venture phase investment company. Stavanger Venture AS was established together with TD Veen AS in 2010. Kjell came from the role as Regional Director Europe North in Cisco Systems. Prior to this, Kjell had several leading positions in TANDBERG ASA that was acquired by Cisco Systems.